ClinicalTrials.gg
CompletedNCT02919319Updated Jul 10, 2018

A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects

A Phase 1 interventional study of ACT-541468 (Formulation A) and ACT-541468 (Formulation B) in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-10.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Feb 2015, registered Sep 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The main objectives of this first-into-man study were to investigate the safety, tolerability and the pharmacokinetic profile of single oral doses of ACT-541468 in healthy male adults. Pharmacodynamic effects (through a battery of Central Nervous System tests) were also assessed.

Read the detailed description

The study consisted of ascending dose groups; each dose group was investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo). In addition, the study included a biocomparison part (dose group 2), an absolute bioavailability part (dose group 4), and a mass balance / metabolism part (dose group 3).

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key inclusion Criteria:

  • Signed prior to any study-mandated procedure.
  • Males aged from 18 to 45 years (inclusive) at screening.
  • (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening.
  • Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) between 100-145 mmHg, 50-90 mmHg and 45-90 bpm (all inclusive) at screening, respectively.
  • Healthy on the basis of physical examination, and laboratory tests.

Key exclusion Criteria:

  • Known to any of the drug formulations.
  • History or presence of any disease or condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study drugs.
  • History of narcolepsy or cataplexy or modified Swiss narcolepsy scale total score \< 0 at screening.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Dose group 1

    Six subjects received 5 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.

    Drug: ACT-541468 (Formulation A) · Drug: Placebo (Formulation A)

  • Experimental
    Dose group 2

    Three subjects received a single oral dose (25 mg) of ACT-541468 formulation A during Period 1 and a single oral dose (25 mg) of ACT-541468 formulation B during Period 2. Three other subjects Subjects received ACT-541468 formulation B during Period 1 and ACT-541468 formulation A during Period 2. Two additional subjects received the matching placebos in both treatment periods.

    Drug: ACT-541468 (Formulation A) · Drug: ACT-541468 (Formulation B) · Drug: Placebo (Formulation A) · Drug: Placebo (Formulation B)

  • Experimental
    Dose group 3

    Six subjects received 50 mg of ACT-541468 (formulation A) as a single oral dose in combination with a \[14C\]-ACT-541468 oral tracer for the mass balance and metabolism analyses. Two other subjects received the matching placebos.

    Drug: ACT-541468 (Formulation A) · Drug: Placebo (Formulation A) · Drug: 14C-labeled ACT-541468 · Drug: Placebo tracer

  • Experimental
    Dose group 4

    Six subjects received 100 mg of ACT-541468 (formulation A) as a single oral dose in combination with a \[14C\]-ACT-541468 intravenous tracer for the absolute bioavailability assessment. Two other subjects received the matching placebos.

    Drug: ACT-541468 (Formulation A) · Drug: Placebo (Formulation A) · Drug: 14C-labeled ACT-541468 · Drug: Placebo tracer

  • Experimental
    Dose group 5

    Six subjects received 200 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.

    Drug: ACT-541468 (Formulation A) · Drug: Placebo (Formulation A)

Interventions

  • Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg

  • Soft gelatin capsules for oral administration formulated at the strength of 25 mg

  • DrugPlacebo (Formulation A)

    Hard capsules matching ACT-541468 Formulation A

  • DrugPlacebo (Formulation B)

    Soft capsules matching ACT-541468 Formulation B

  • Drug14C-labeled ACT-541468

    Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously

  • DrugPlacebo tracer

    Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.

06

What researchers measure

Primary outcomes

  1. Number of subjects with treatment-emergent adverse events and serious adverse events

    Collection of any adverse event at each dose level

    Time frame: Day 8

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of ACT-541468

    Cmax was directly derived from the observed plasma concentrations of ACT-541468 for each dose level

    Time frame: From pre-dose up to 168 hours post-dose

  2. Time to reach Cmax (tmax) of ACT-541468

    tmax was directly derived from the observed plasma concentrations of ACT-541468 for each dose level

    Time frame: From pre-dose up to 168 hours post-dose

  3. Terminal half-life (t1/2) of ACT-541468

    t1/2 was calculated from the terminal rate constant obtained from the plasma concentrations-time curves of ACT-541468, at each dose level

    Time frame: From pre-dose up to 168 hours post-dose

  4. Area under the plasma concentration-time curves [AUC(0-inf)] of ACT-541468

    AUC(0-inf) is the area under the plasma concentration-time curves of ACT-541468, calculated from time 0 (pre-dose) to extrapolated infinite time, at each dose level

    Time frame: From pre-dose up to 168 hours post-dose

  5. Percentage of dose excreted in feces and urine

    Percentage of oral dose of 14C-labeled ACT-541468 excreted in feces (FPE), urine (UPE) and both, as determined in the dose group 3

    Time frame: From pre-dose up to 168 hours post-dose

  6. Absolute bioavailability (F) of ACT-541468

    Absolute bioavailability was determined for dose group 4 and defined as the ratio of AUC(0-inf) after oral administration of ACT-541468 and after intravenous infusion of 14C-labeled ACT-541468 (tracer)

    Time frame: Up to 96 hours post-dose

Other outcomes

  1. Change from baseline in saccadic peak velocity (SPV)

    Time frame: At baseline till 10 hours after study drug administration

  2. Change from baseline in body sway

    Time frame: At baseline till 10 hours after study drug administration

  3. Change from baseline in adaptive tracking

    Time frame: At baseline till 10 hours after study drug administration

  4. Chnage from baseline in Bond and Lader visual analog scale (B&L VAS)l

    Time frame: At baseline till 10 hours after study drug administration

07

Study locations

1 site
  • Investigator Site
    Leiden, 2333 CL, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in May 2015, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2016
First posted
Sep 29, 2016
StartActual
Feb 1, 2015
Primary completionActual
May 1, 2015
CompletionActual
May 1, 2015
Last update
Jul 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02919319
Responsible party
Sponsor
First posted
Sep 29, 2016
Start date
Feb 1, 2015
Primary completion
May 1, 2015
Completion
May 1, 2015
Last update
Jul 10, 2018

Study contacts

Clemens Muehlan
study director · Actelion
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion